

FEB 16 2010

CLAIMS

Claims 1-31 were originally filed. Claims 1, 2, 4, 6-9, 11-19, 21, 23-28, and 30 are currently pending in this application. Claims 3, 10, 20, 22, 29 and 31 were previously cancelled without prejudice or disclaimer of the subject matter thereof. Claims 5 and 19 are herein cancelled without prejudice or disclaimer of the subject matter herein. Claims 18 and 27 are herein amended without prejudice or disclaimer of the subject matter therein.

In the Claims

1. (Original) A method for treatment of an individual demonstrating behavioral characteristics associated with autism comprising the steps of:
administering to said individual a composition comprising a therapeutically effective amount of oxytocin.
2. (Original) The method of claim 1, wherein said oxytocin is an oxytocin analog selected from the group consisting of 4-threonine-1-hydroxy-deaminooxytocin, 9-deamidooxytocin, 7-D-proline-oxytocin and its deamino analog, (2,4-diisoleucine)-oxytocin, deamino oxytocin analog, 1-deamino-1-monocarba-E12-[Tyr (OMe)]-OT(dCOMOT), carbetocin, Ile-conopressin, atosiban, [Thr4-Gly7]-oxytocin, oxypressin, deamino-6-carba-oxytocin (dC60), d[Lys(8)(5/6C-Flu)]VT, d[Thr(4),Lys(8)(5/6C-Flu)]VT, [HO(1)][Lys(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Lys(8)(5/6C-Flu)]VT, d[Orn(8)(5/6C-Flu)]VT, d[Thr(4),Orn(8)(5/6C-Flu)]VT, [HO(1)][Orn(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Orn(8)(5/6C-Flu)]VT and oxytocin fragments.
3. (Previously Cancelled)
4. (Original) The method of claim 1 wherein said therapeutically effective amount of oxytocin ranges from 0.1 unit per hour to 7 units per hour.
5. (Cancelled)

6. (Original) In a method for treatment of an individual, demonstrating behavioral characteristics associated with autism by administration of psychopharmacologic agents, the improvement comprising:

additional administration of a therapeutically effective amount of a composition comprising oxytocin, oxytocin analog or combination thereof.

7. (Original) The method of claim 6 wherein said oxytocin is an oxytocin analog selected from the group consisting of 4-threonine-1-hydroxy-deaminooxytocin, 9-deamidooxytocin, 7-D-proline-oxytocin and its deamino analog, (2,4-diisoleucine)-oxytocin, deamino oxytocin analog, 1-deamino-1-monocarba-E12-[Tyr (OMe)]-OT(dCOMOT), carbetocin, Ile-conopressin, atosiban, [Thr4-Gly7]-oxytocin, oxypressin, deamino-6-carba-oxytocin (dC60), d[Lys(8)(5/6C-Flu)]VT, d[Thr(4),Lys(8)(5/6C-Flu)]VT, [HO(1)][Lys(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Lys(8)(5/6C-Flu)]VT, d[Orn(8)(5/6C-Flu)]VT, d[Thr(4),Orn(8)(5/6C-Flu)]VT, [HO(1)][Orn(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Orn(8)(5/6C-Flu)]VT and oxytocin fragments.

8. (Original) The method of claim 6, wherein said psychopharmacologic agent is selected from the group consisting of sedatives, tranquilizers, antipsychotics, antidepressants and anticonvulsants.

9. (Original) The method of claim 6, wherein said psychopharmacologic agent affects the opiate, noradrenergic, dopaminergic, serotonergic, glutamatergic and GABAergic systems.

10. (Previously Cancelled)

11. (Original) The method of claim 6 wherein said therapeutically effective amount ranges from 0.1 unit per hour to 7 units per hour.

12. (Original) The method of claim 6 wherein said composition is oxytocin.

13. (Original) A method for treatment of an individual demonstrating behavioral characteristics associated with autism comprising the steps of:

a) administering an oxytocin solution intravenously to said individual for four hours, the dose rate of said solution initially to be at 0.1 unit per hour to increase every 15 minutes of the first hour by .25 units per hour, said dose rate of said solution to be increased every 15 minutes of the second hour by 0.5 unit per hour, said dose rate of said solution to be increased every 15 minutes of the third hour by 1 unit per hour and said dose rate of said solution to remain constant at 7 units per hour the fourth hour.

14. (Original) A method for treatment of an individual demonstrating repetitive behaviors, social deficits or cognitive deficits comprising the steps of:

a) administering an oxytocin solution intravenously to said individual for four hours, the dose rate of said solution initially to be at 0.1 unit per hour to increase every 15 minutes of the first hour by .25 units per hour, said dose rate of said solution to be increased every 15 minutes of the second hour by 0.5 unit per hour, said dose rate of said solution to be increased every 15 minutes of the third hour by 1 unit per hour and said dose rate of said solution to remain constant at 7 units per hour the fourth hour.

15. (Original) A method for treatment of an individual with a disorder including repetitive behaviors, social deficits and cognitive deficits comprising the steps of:

administering to said individual a composition comprising a therapeutically effective amount of oxytocin.

16. (Original) The method of claim 15, wherein said oxytocin is an oxytocin analog selected from the group consisting of 4-threonine-1-hydroxy-deaminooxytocin, 9-deamidooxytocin, 7-D-proline-oxytocin and its deamino analog, (2,4-diisoleucine)-oxytocin, deamino oxytocin analog, 1-deamino-1-monocarba-E12-[Tyr (OMe)]-OT(dCOMOT), carbetocin, Ile-conopressin, atosiban, [Thr4-Gly7]-oxytocin, oxypressin, deamino-6-carba-oxytocin (dC60), d[Lys(8)(5/6C-Flu)]VT, d[Thr(4),Lys(8)(5/6C-Flu)]VT, [HO(1)][Lys(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Lys(8)(5/6C-

Flu)]VT, d[Orn(8)(5/6C-Flu)]VT, d[Thr(4),Orn(8)(5/6C-Flu)]VT, [HO(1)][Orn(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Orn(8)(5/6C-Flu)]VT and oxytocin fragments.

17. (Original) The method of claim 15 wherein said behavioral characteristic associated with autism is selected from the group consisting of a repetitive behavior, a deficit in social awareness and a deficit in cognitive skills.

18. (Currently Amended) The method of claim 15, wherein said therapeutically effective amount of oxytocin, oxytocin analog or combination thereof is ~~10ug/mL~~ 10 units per ml oxytocin dissolved into 1000 mL normal saline, administered at a rate of 10 milliunits per minute or 6 units/hour.

19. (Cancelled)

20. (Previously Cancelled)

21. (Previously Amended) The method of claim 15, wherein said disorder including social deficits is Social Anxiety Disorder.

22. (Previously Cancelled)

23. (Original) In a method for treatment of an individual with a disorder including repetitive behaviors, social deficits and cognitive deficits, by administration of psychopharmacologic agents, the improvement comprising:

additional administration of a therapeutically effective amount of a composition comprising oxytocin, oxytocin analog or combination thereof.

24. (Previously Amended) The method of claim 23 wherein said oxytocin is an oxytocin analog selected from the group consisting of 4-threonine-1-hydroxy-deaminooxytocin, 9-

deamidooxytocin, 7-D-proline-oxytocin and its deamino analog, (2,4-diisoleucine)-oxytocin, deamino oxytocin analog, 1-deamino-1-monocarba-E12-[Tyr (OMe)]-OT(dCOMOT), carbetocin, Ile-conopressin, atosiban, [Thr4-Gly7]-oxytocin, oxypressin, deamino-6-carba-oxytocin (dC60), d[Lys(8)(5/6C-Flu)]VT, d[Thr(4),Lys(8)(5/6C-Flu)]VT, [HO(1)][Lys(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Lys(8)(5/6C-Flu)]VT, d[Orn(8)(5/6C-Flu)]VT, d[Thr(4),Orn(8)(5/6C-Flu)]VT, [HO(1)][Orn(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Orn(8)(5/6C-Flu)]VT and oxytocin fragments.

25. (Original) The method of claim 23, wherein said psychopharmacologic agent is selected from the group consisting of sedatives, tranquilizers, antipsychotics, antidepressants and anticonvulsants.

26. (Original) The method of claim 23, wherein said psychopharmacologic agent affects the opiate, noradrenergic, dopaminergic, serotonergic, glutamatergic and GABAergic systems.

27. (Currently Amended) The method of claim 23 wherein said therapeutically effective amount is ~~10ug/mL~~ 10 units per ml oxytocin dissolved into 1000 mL normal saline, administered at a rate of 10 milliunits per minute or 6 units/hour.

28. (Original) The method of claim 23 wherein said composition is oxytocin.

29. (Previously Cancelled)

30. (Previously Amended) The method of claim 23, wherein said disorder including social deficits is Social Anxiety Disorder.

31. (Previously Cancelled)